NKT-3447 is under clinical development by NiKang Therapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase ...

NKT-3447 is under clinical development by NiKang Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate ...

Show referrer list on panel or markdown view(auto or manually) Display reference's detail of every referrer Show referrer of every element with id Jump and scroll to ...

This roadmap aims to nurture, promote and facilitate Home Languages across education systems in Europe. It provides resources at a transnational, national, regional and local school-policy level. It ...

YLC co-chairperson Zandile Mathabo Makhaya said she is delighted about this year’s awards ceremony, which will unveil a new ...

YourLifeChoices is Australia’s most established and trusted digital publication for the 50+ audience, with a core focus on helping Australians navigate midlife and the retirement landscape. Since 2000 ...

This is the product's overall performance score, based on key tests conducted by our industry experts in the CHOICE labs.